Pear Therapeutics Archives | Arboretum Ventures

Pear Therapeutics to Be Added to Russell US Index Series

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription…

Arboretum_JDAugust 3, 2022

Home Page News Page Pear Therapeutics

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Company

Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription…

Arboretum_JDDecember 6, 2021

News Page Pear Therapeutics

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics…

Arboretum_JDNovember 23, 2021

News Page Pear Therapeutics

Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRX

Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the…

Arboretum_JDAugust 10, 2021

News Page Pear Therapeutics

Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact…

Arboretum_JDJuly 28, 2021

Home Page News Page Pear Therapeutics

Pear Therapeutics to Become a Public Company

Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing prescription digital therapeutics (PDTs) to…

Arboretum_JDJune 22, 2021

Pear Therapeutics

Pear Therapeutics Announces Second Closing of Series D Financing

Pear Therapeutics, Inc., recently announced the second closing of its Series D financing. The second…

Arboretum_JDMarch 3, 2021

Home Page News Page Pear Therapeutics

Pear Therapeutics Completes $80M Series D Financing Led by Softbank Vision Fund 2

Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced that it has successfully closed an…

Arboretum_JDDecember 8, 2020

Pear Therapeutics

Pear Therapeutics Launches Somryst for the Treatment of Chronic Insomnia

Pear Therapeutics, Inc., recently announced the availability of Somryst™, the first prescription digital therapeutic (PDT)…

Arboretum_JDNovember 17, 2020

Pear Therapeutics

Pear Therapeutics Wins Prix Galien USA Award for Somryst™ as Best Digital Health Product

Pear Therapeutics, Inc. recently announced that the Galien Foundation has awarded the 2020 Prix Galien…

Arboretum_JDNovember 2, 2020

Pear Therapeutics

Pear Therapeutics to Be Added to Russell US Index Series

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Company

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRX

Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Pear Therapeutics to Become a Public Company

Pear Therapeutics Announces Second Closing of Series D Financing

Pear Therapeutics Completes $80M Series D Financing Led by Softbank Vision Fund 2

Pear Therapeutics Launches Somryst for the Treatment of Chronic Insomnia

Pear Therapeutics Wins Prix Galien USA Award for Somryst™ as Best Digital Health Product

News & Insights

ARCHIVES